 |
53 Diseases |  |
2 Trials |
|
2 Trials |  |
95 News |  |
| «12 |
- | iniparib (BSI 201) / Sanofi
Trial completion, PARP Biomarker, Metastases: Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma (clinicaltrials.gov) - May 22, 2012
P2, N=22, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed
- | iniparib (BSI 201) / Sanofi
Enrollment open, Monotherapy: Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial (clinicaltrials.gov) - May 9, 2012
P3, N=41, Recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| iniparib (BSI 201) / Sanofi
New P3 trial, Monotherapy: Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial (clinicaltrials.gov) - May 6, 2012
P3, N=41, Recruiting, Sponsor: Sanofi
- ||||||| iniparib (BSI 201) / Sanofi
Trial completion, PARP Biomarker, Metastases: A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer (clinicaltrials.gov) - May 6, 2012
P3, N=519, Completed, Sponsor: Sanofi
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- iniparib (BSI 201) / Sanofi
New P1 trial: RAPIBE: A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases (clinicaltrials.gov) - Mar 11, 2012
P1, N=30, Recruiting, Sponsor: Centre Val d'Aurelle - Paul Lamarque
- ||| iniparib (BSI 201) / Sanofi
Enrollment closed, Combination therapy, PARP Biomarker: SOLTI NEOPARP: Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Jan 3, 2012
P2, N=141, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| iniparib (BSI 201) / Sanofi
Trial completion, Combination therapy, Metastases: SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 3, 2012
P2, N=119, Completed, Sponsor: Sanofi
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| iniparib (BSI 201) / Sanofi
Trial completion, Combination therapy, PARP Biomarker, Metastases: A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Dec 5, 2011
P1b, N=136, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | iniparib (BSI 201) / Sanofi
Trial completion, Metastases: Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Nov 15, 2011
P2, N=12, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| iniparib (BSI 201) / Sanofi
New P1 trial, Combination therapy, PARP Biomarker: A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors (clinicaltrials.gov) - Oct 18, 2011
P1, N=160, Active, not recruiting, Sponsor: Sanofi
- iniparib (BSI 201) / Sanofi
Trial completion, Metastases: An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 (clinicaltrials.gov) - Aug 9, 2011
P1, N=7, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed